NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026
Rhea-AI Summary
NeurAxis (NYSE American: NRXS) will report summarized fourth quarter and full year 2025 results for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open.
The company will host a conference call and live webcast on March 19, 2026 at 9:00am ET; webcast and replay will be available in the Investor Relations section of the company's website. Participants can submit questions via the webcast portal or by emailing NRXS@lythampartners.com.
Positive
- None.
Negative
- None.
News Market Reaction – NRXS
On the day this news was published, NRXS gained 0.47%, reflecting a mild positive market reaction. Argus tracked a peak move of +10.6% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $370K to the company's valuation, bringing the market cap to $79M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NRXS was up 2.22% while close peers showed mixed moves: AKTX and ICU down, FBLG sharply down, LIXT and RNTX up. Momentum scanner flags SABS and FBLG up, AKTX down, reinforcing a stock-specific backdrop for NRXS.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 11 | Q3 2025 earnings | Positive | -5.9% | Reported 22% YoY revenue growth and multiple FDA clearances for IB-Stim. |
| Aug 12 | Q2 2025 earnings | Positive | +2.5% | Revenues grew 46% YoY with lower operating expenses and improved loss. |
| May 12 | Q1 2025 earnings | Positive | +16.0% | Revenues increased 39% YoY and covered lives expanded sharply. |
| Mar 20 | Q4 2024 earnings | Positive | -0.9% | Q4 revenue up 43% and FY2024 revenue up 9% versus 2023. |
| Jan 08 | Prelim Q4 2024 | Positive | -3.9% | Preliminary Q4 showed ~50% revenue growth and full-year revenue up 11%. |
Earnings releases are typically framed as strong, but price reactions have been mixed, with more divergences (down moves on positive news) than alignments.
Across prior earnings, NeurAxis reported consistent revenue growth with Q1–Q3 2025 revenues rising 39%, 46%, and 22% year-over-year, plus sequential expansion of covered lives and multiple FDA clearances. Despite these positive trends, stock reactions varied, sometimes declining after strong results. Today’s scheduling of Q4 2025 and full-year 2025 results continues this cadence of frequent financial updates and operational progress communication.
Historical Comparison
Prior earnings and preliminary results produced an average move of 1.58%, with several instances of weak or negative reactions despite strong growth.
Earnings updates show sustained revenue growth from Q4 2024 into Q1–Q3 2025, alongside expanding covered lives and repeated FDA clearances.
Market Pulse Summary
This announcement schedules NeurAxis’ Q4 and full-year 2025 results for March 19, 2026, continuing a steady cadence of detailed financial updates. Prior quarters showed strong revenue growth and expanding insurance coverage, but share reactions were mixed. Investors may focus on whether momentum from earlier periods persists, how operating losses and cash evolve, and how new reimbursement and coverage wins translate into sustainable revenue and margin trends.
AI-generated analysis. Not financial advice.
CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2025, for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open. The Company has scheduled a conference call for the same day, Thursday, March 19, 2026, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Thursday, March 19, 2026, at 9:00am ET
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/4ig827me. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com.
Call-in Information: Interested parties can also access the live conference call by initially registering at the following link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/4ig827me.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.
For more information, please visit http://neuraxis.com.
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
FAQ
When will NeurAxis (NRXS) report Q4 and full year 2025 results?
How can investors join the NeurAxis (NRXS) March 19, 2026 earnings call?
Where will the NeurAxis (NRXS) webcast and replay be posted?
What time is the NeurAxis (NRXS) conference call on March 19, 2026?
How can participants submit questions during the NeurAxis (NRXS) webcast?
Will there be a replay of the NeurAxis (NRXS) March 19, 2026 call and how long will it be available?
